Huan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huan Li has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Bo Gong
Sichuan Provincial People's Hospital Sichuan Provincial Key Laboratory for Human Disease Gene Study Sichuan Academy of Medical Sciences & University of Electronic Science and Technology of China Chengdu Sichuan China
3 shared publications Jialing Xiao
Department of Health Management, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital School of Medicine, University of Electronic Science and Technology of China Chengdu Sichuan China
3 shared publicationsChenglong Li
Department of hematology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China
2 shared publicationsGuilherme Valente
Clinical Hospital of Medicine School of Botucatu UNESP São Paulo Brazil
2 shared publicationsJun Zhou
School of Biomedical Sciences Hunan University Changsha Hunan Province China
2 shared publicationsLan Luo
Chengdu University of Traditional Chinese Medicine
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Wiley in Medicine Bulletin
- Vol. 2 (4) , 388-405
Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints
Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention. This residual risk is not monolithic: It reflects mechanistically distinct drivers, including lesion‐level structural differences, inflammation amplified by clonal hematopoiesis of indeterminate potential (CHIP), and genetically anchored lipoprotein liabilities that conventional lipid lowering does not adequately modify. We propose an executable framework for individualized atherosclerosis therapy that organizes clinical decision‐making around three axes: actionable endotype identification, selection of a matched therapeutic modality, and evaluation of delivery feasibility. Programmable medicines, particularly liver‐directed siRNA and antisense oligonucleotides, have expanded what is therapeutically reachable for hepatic targets, whereas gene editing offers the prospect of permanent risk modification under a higher safety and evidentiary bar. Delivery innovations and multiomic‐ and imaging‐based AI further determine which endotype hypotheses can advance into scalable interventions. Together, this endotype–target–delivery logic aims to shift ASCVD care from empiric stacking toward decision pathways that are mechanistically anchored, diagnostically implementable, and clinically testable.
- 24 September 2026
- Published by Wiley in Medicine Bulletin
- Vol. 2 (4) , 388-405
Open AccessToward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints
Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention. This residual risk is not monolithic: It reflects mechanistically distinct drivers, including lesion‐level structural differences, inflammation amplified by clonal hematopoiesis of indeterminate potential (CHIP), and genetically anchored lipoprotein liabilities that conventional lipid lowering does not adequately modify. We propose an executable framework for individualized atherosclerosis therapy that organizes clinical decision‐making around three axes: actionable endotype identification, selection of a matched therapeutic modality, and evaluation of delivery feasibility. Programmable medicines, particularly liver‐directed siRNA and antisense oligonucleotides, have expanded what is therapeutically reachable for hepatic targets, whereas gene editing offers the prospect of permanent risk modification under a higher safety and evidentiary bar. Delivery innovations and multiomic‐ and imaging‐based AI further determine which endotype hypotheses can advance into scalable interventions. Together, this endotype–target–delivery logic aims to shift ASCVD care from empiric stacking toward decision pathways that are mechanistically anchored, diagnostically implementable, and clinically testable.
- Open Access
- 14 January 2026
- Published by Wiley in Medicine Bulletin
- Vol. 2 (1) , 94-123
Emerging Therapeutic Strategies in Anti‐Aging Medicine: A Comprehensive Review
Aging is orchestrated by interconnected hallmarks such as genomic instability, mitochondrial dysfunction, cellular senescence, and disrupted intercellular communication, which collectively drive chronic disease progression. Recent advances have expanded therapeutic opportunities to include pharmacological agents, gene and epigenome editing, stem cell based interventions, microbiome modulation, and nanomedicine. Artificial intelligence and multi‐omics integration are further accelerating target discovery and patient stratification. This review synthesizes these modalities within a unified framework that explicitly links hallmarks to biomarkers and therapeutic strategies, critically evaluates preclinical versus clinical outcomes, and examines why promising interventions often fail to translate. We propose an integrative model emphasizing biomarker alignment, phenotype stratification, and regulatory adaptation. By embedding mechanistic insights into clinically predictive and patient‐centered designs, this review outlines a roadmap for advancing gerotherapeutics to extend healthspan.
- 14 January 2026
- Published by Wiley in Medicine Bulletin
- Vol. 2 (1) , 94-123
Open AccessEmerging Therapeutic Strategies in Anti‐Aging Medicine: A Comprehensive Review
Aging is orchestrated by interconnected hallmarks such as genomic instability, mitochondrial dysfunction, cellular senescence, and disrupted intercellular communication, which collectively drive chronic disease progression. Recent advances have expanded therapeutic opportunities to include pharmacological agents, gene and epigenome editing, stem cell based interventions, microbiome modulation, and nanomedicine. Artificial intelligence and multi‐omics integration are further accelerating target discovery and patient stratification. This review synthesizes these modalities within a unified framework that explicitly links hallmarks to biomarkers and therapeutic strategies, critically evaluates preclinical versus clinical outcomes, and examines why promising interventions often fail to translate. We propose an integrative model emphasizing biomarker alignment, phenotype stratification, and regulatory adaptation. By embedding mechanistic insights into clinically predictive and patient‐centered designs, this review outlines a roadmap for advancing gerotherapeutics to extend healthspan.
- Open Access
- 15 October 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (10) , e70276
Serum Levels of 54 Cytokines and Chemokines Reveal Distinct Inflammatory Signatures in Ankylosing Spondylitis
Background: Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disorder predominantly involving the axial skeleton. Understanding the cytokine and chemokine signatures in AS is crucial for elucidating disease mechanisms and identifying potential diagnostic biomarkers. Methods: Serum samples from 31 AS patients and 20 age‐matched healthy controls (HCs) were analyzed. The concentrations of 54 cytokines, chemokines, and angiogenesis‐related factors were measured using a Meso Scale Discovery (MSD) electrochemiluminescence immunoassay. Data analysis included statistical comparison of serum cytokine levels, heatmap clustering, principal component analysis (PCA), and receiver operating characteristic (ROC) curve analysis. Validation was performed using peripheral blood mononuclear cells (PBMCs) from SKG mice, a spontaneous animal model of AS, through quantitative real‐time PCR. Results: Compared with HCs, AS patients showed significantly higher serum concentrations of 12 cytokines (TNF‐α, TNF‐β, IL‐17A, IL‐17D, VEGFA, ICAM1, SAA, IP‐10/CXCL10, MIP‐3α/CCL20, sFlt‐1/VEGFR‐1, CRP, and MCP‐4/CCL13) and significantly lower concentrations of nine cytokines (IL‐4, IL‐8, IL‐17C, MIP‐1α/CCL3, eotaxin‐3/CCL26, PlGF, VEGF‐C, VEGF‐D, and bFGF) (all p < 0.05). Heatmap clustering and PCA demonstrated a clear separation between AS patients and HCs. ROC curve analysis showed excellent diagnostic accuracy for IP‐10/CXCL10 (AUC = 1.00), VEGF‐D (AUC = 0.98), IL‐17A (AUC = 0.87), TNF‐α (AUC = 0.85), and ICAM1 (AUC = 0.84). Positive correlations were observed between IL‐17A and MIP‐3α/CCL20, and between VEGFA and sFlt‐1, indicating coordinated inflammatory and angiogenic pathways. Validation experiments in SKG mice confirmed elevated IP‐10/CXCL10 and reduced VEGF‐D expression, supporting cross‐species relevance. Conclusions: This study identified distinct cytokine and chemokine profiles in AS patients. IP‐10/CXCL10 and VEGF‐D emerged as promising diagnostic biomarkers with high discriminatory power. Several previously unreported immune mediators were also highlighted. These findings provide new insights into AS pathogenesis and suggest potential targets for future therapeutic interventions.
- 15 October 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (10) , e70276
Open AccessSerum Levels of 54 Cytokines and Chemokines Reveal Distinct Inflammatory Signatures in Ankylosing Spondylitis
Background: Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disorder predominantly involving the axial skeleton. Understanding the cytokine and chemokine signatures in AS is crucial for elucidating disease mechanisms and identifying potential diagnostic biomarkers. Methods: Serum samples from 31 AS patients and 20 age‐matched healthy controls (HCs) were analyzed. The concentrations of 54 cytokines, chemokines, and angiogenesis‐related factors were measured using a Meso Scale Discovery (MSD) electrochemiluminescence immunoassay. Data analysis included statistical comparison of serum cytokine levels, heatmap clustering, principal component analysis (PCA), and receiver operating characteristic (ROC) curve analysis. Validation was performed using peripheral blood mononuclear cells (PBMCs) from SKG mice, a spontaneous animal model of AS, through quantitative real‐time PCR. Results: Compared with HCs, AS patients showed significantly higher serum concentrations of 12 cytokines (TNF‐α, TNF‐β, IL‐17A, IL‐17D, VEGFA, ICAM1, SAA, IP‐10/CXCL10, MIP‐3α/CCL20, sFlt‐1/VEGFR‐1, CRP, and MCP‐4/CCL13) and significantly lower concentrations of nine cytokines (IL‐4, IL‐8, IL‐17C, MIP‐1α/CCL3, eotaxin‐3/CCL26, PlGF, VEGF‐C, VEGF‐D, and bFGF) (all p < 0.05). Heatmap clustering and PCA demonstrated a clear separation between AS patients and HCs. ROC curve analysis showed excellent diagnostic accuracy for IP‐10/CXCL10 (AUC = 1.00), VEGF‐D (AUC = 0.98), IL‐17A (AUC = 0.87), TNF‐α (AUC = 0.85), and ICAM1 (AUC = 0.84). Positive correlations were observed between IL‐17A and MIP‐3α/CCL20, and between VEGFA and sFlt‐1, indicating coordinated inflammatory and angiogenic pathways. Validation experiments in SKG mice confirmed elevated IP‐10/CXCL10 and reduced VEGF‐D expression, supporting cross‐species relevance. Conclusions: This study identified distinct cytokine and chemokine profiles in AS patients. IP‐10/CXCL10 and VEGF‐D emerged as promising diagnostic biomarkers with high discriminatory power. Several previously unreported immune mediators were also highlighted. These findings provide new insights into AS pathogenesis and suggest potential targets for future therapeutic interventions.
- Open Access
- 26 January 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (4) , e36948
Acute undifferentiated leukemia with undifferentiated myeloid sarcoma: Case report and literature review
Background: With the advancement of diagnostic technology, true acute undifferentiated leukemia (AUL) is becoming more rare, and AUL with extramedullary sarcoma has not been reported. Case presentation: This article reports a case of AUL with extramedullary sarcoma. Flow cytometric analysis of the bone marrow and lymph nodes indicated that the tumor cells of both were of the same origin and mainly expressed stem cell markers and CD7, no myeloid-specific markers, T-lymphoblastic-related markers, and B-lymphoblastic-related markers. Although the priming regimen combined with azacitidine was ineffective, complete remission was achieved by switching to azacitidine combined with HIA (homoharringtonine, idarubicin plus Ara-C). Conclusion: To diagnosis de novo acute leukemia with extensive and comprehensive cellular immune maker detection is available and credible, the expression of a single relatively nonspecific myeloid antigen as a immune maker to detect AUL or AUL associated with sarcoma is precise and effective in our case, which patient was benefit from HIA regiment.
- 26 January 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (4) , e36948
Open AccessAcute undifferentiated leukemia with undifferentiated myeloid sarcoma: Case report and literature review
Background: With the advancement of diagnostic technology, true acute undifferentiated leukemia (AUL) is becoming more rare, and AUL with extramedullary sarcoma has not been reported. Case presentation: This article reports a case of AUL with extramedullary sarcoma. Flow cytometric analysis of the bone marrow and lymph nodes indicated that the tumor cells of both were of the same origin and mainly expressed stem cell markers and CD7, no myeloid-specific markers, T-lymphoblastic-related markers, and B-lymphoblastic-related markers. Although the priming regimen combined with azacitidine was ineffective, complete remission was achieved by switching to azacitidine combined with HIA (homoharringtonine, idarubicin plus Ara-C). Conclusion: To diagnosis de novo acute leukemia with extensive and comprehensive cellular immune maker detection is available and credible, the expression of a single relatively nonspecific myeloid antigen as a immune maker to detect AUL or AUL associated with sarcoma is precise and effective in our case, which patient was benefit from HIA regiment.
- Open Access
- 31 October 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)
Multiple myeloma (MM) accounts for ~10% of all haematologic malignancies. Little is known about high intratumour heterogeneities in patients stratified by the Revised International Staging System (R-ISS). Herein, we constructed a single-cell transcriptome atlas to compare differential expression patterns among stages. We found that a novel cytotoxic plasma cell (PC) population exhibited with NKG7 positive was obviously enriched in stage II patients. Additionally, a malignant PC population with significantly elevated expression of MKI67 and PCNA was associated with unfavourable prognosis and Epstein-Barr virus (EBV) infection in our collected samples. Moreover, ribonucleotide reductase regulatory subunit M2 (RRM2) was found and verified to promote proliferation of MM cell lines, suggesting RRM2 may serve as a detrimental marker in MM. The percentages of CD8+ T cells and NKT cells decreased along with R-ISS stages, reflecting the plasticity of the tumour immune microenvironment. Importantly, their crosstalks with myeloid cells and PC identified several potential immunotargets such as SIRPA-CD47 and CD74-MIF, respectively. Collectively, this study provided an R-ISS-related single-cell MM atlas and revealed the clinical significance of novel PC clusters, as well as potential immunotargets in MM progression.
- 31 October 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessRevised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM)
Multiple myeloma (MM) accounts for ~10% of all haematologic malignancies. Little is known about high intratumour heterogeneities in patients stratified by the Revised International Staging System (R-ISS). Herein, we constructed a single-cell transcriptome atlas to compare differential expression patterns among stages. We found that a novel cytotoxic plasma cell (PC) population exhibited with NKG7 positive was obviously enriched in stage II patients. Additionally, a malignant PC population with significantly elevated expression of MKI67 and PCNA was associated with unfavourable prognosis and Epstein-Barr virus (EBV) infection in our collected samples. Moreover, ribonucleotide reductase regulatory subunit M2 (RRM2) was found and verified to promote proliferation of MM cell lines, suggesting RRM2 may serve as a detrimental marker in MM. The percentages of CD8+ T cells and NKT cells decreased along with R-ISS stages, reflecting the plasticity of the tumour immune microenvironment. Importantly, their crosstalks with myeloid cells and PC identified several potential immunotargets such as SIRPA-CD47 and CD74-MIF, respectively. Collectively, this study provided an R-ISS-related single-cell MM atlas and revealed the clinical significance of novel PC clusters, as well as potential immunotargets in MM progression.
- Open Access
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma
Multiple myeloma (MM), characterized by high intratumour heterogeneity, accounts for ∼10% of all haematologic malignancies. Stratified by the Revised International Staging System (R-ISS), little is known about R-ISS-related plasma cell (PC) heterogeneity, gene expression modules in cytotoxic T/NK cells and immunoregulatory ligands and receptors. Herein, we constructed a single-cell transcriptome atlas of bone marrow in normal and R-ISS-staged MM patients. Focusing on PCs, we identified and validated a subset of GZMA+ cytotoxic PCs. In addition, a malignant PC population with high proliferation capability (proliferating PCs) was associated with unfavourable prognosis and EBV infection in our collected samples. Ribonucleotide Reductase Regulatory Subunit M2 (RRM2), a specific marker of proliferating PCs, was shown to induce MM cell line proliferation and serve as a detrimental marker in MM. Subsequently, three R-ISS-dependent gene modules in cytotoxic CD8+ T and NKT cells were identified and functionally analysed. Finally, cell-cell communication between neutrophils and proliferating PCs with cytotoxic CD8+ T and NKT cells was investigated, which identified intercellular ligand receptors and potential immunotargets such as SIRPA-CD47 and TIGIT-NECTIN3. Collectively, this study provides an R-ISS-related single-cell MM atlas and reveals the clinical significance of two PC clusters, as well as potential immunotargets in MM progression.
Open AccessRevised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma
Multiple myeloma (MM), characterized by high intratumour heterogeneity, accounts for ∼10% of all haematologic malignancies. Stratified by the Revised International Staging System (R-ISS), little is known about R-ISS-related plasma cell (PC) heterogeneity, gene expression modules in cytotoxic T/NK cells and immunoregulatory ligands and receptors. Herein, we constructed a single-cell transcriptome atlas of bone marrow in normal and R-ISS-staged MM patients. Focusing on PCs, we identified and validated a subset of GZMA+ cytotoxic PCs. In addition, a malignant PC population with high proliferation capability (proliferating PCs) was associated with unfavourable prognosis and EBV infection in our collected samples. Ribonucleotide Reductase Regulatory Subunit M2 (RRM2), a specific marker of proliferating PCs, was shown to induce MM cell line proliferation and serve as a detrimental marker in MM. Subsequently, three R-ISS-dependent gene modules in cytotoxic CD8+ T and NKT cells were identified and functionally analysed. Finally, cell-cell communication between neutrophils and proliferating PCs with cytotoxic CD8+ T and NKT cells was investigated, which identified intercellular ligand receptors and potential immunotargets such as SIRPA-CD47 and TIGIT-NECTIN3. Collectively, this study provides an R-ISS-related single-cell MM atlas and reveals the clinical significance of two PC clusters, as well as potential immunotargets in MM progression.